Rate My Professor Soheil Meshinchi

Soheil Meshinchi, MD, PhD, is a Professor in the Translational Science and Therapeutics Division at Fred Hutch Cancer Center and a Professor in the Division of Pediatric Hematology/Oncology at the University of Washington School of Medicine. He earned his MD from Wayne State University in 1994, PhD in Pharmacology/Protein Biochemistry from the University of Michigan in 1990, and BS in Microbiology from the University of Michigan in 1984. Dr. Meshinchi completed his residency in Pediatrics at Johns Hopkins Hospital in 1997 and fellowship training in Pediatric Hematology and Oncology at the University of Washington and Fred Hutchinson Cancer Center in 2000, followed by a Research Associate position at Fred Hutch from 2000 to 2002. He serves as an Attending Physician in Pediatric Hematology Oncology at Seattle Children's Hospital and Fred Hutch, Chair of the Children's Oncology Group (COG) Myeloid Disease Biology Committee, Vice Chair of the COG Myeloid Disease Committee, Director of the COG AML Cell and Nucleic Acid Repository, and Director of the COG Hematopoietic Integrated Translational Science Center. In March 2026, he was appointed the Dylan Burke Endowed Chair in Immunotherapy and is a member of the Immunotherapy Integrated Research Center at Fred Hutch.

In the field of Medicine, Dr. Meshinchi specializes in leukemia biology, with a focus on acute myeloid leukemia in children and young adults, peripheral blood stem cell transplantation, post-transplant relapse management, and targeted therapies. His laboratory leads the largest genome and transcriptome sequencing project in pediatric and young adult AML, maintaining a biorepository of over 100,000 specimens from more than 3,000 patients. He provides scientific leadership for national and international committees and has developed clinical assays for cooperative group trials, including those assessing minimal residual disease and sensitivities to novel therapeutics. Dr. Meshinchi has clarified the prognostic significance of FLT3 mutations and other receptor tyrosine kinase alterations in aggressive pediatric AML cases. His work has advanced immunotherapy targets such as FOLR1 for infant leukemia and PRAME, leading to first-in-human CAR T-cell therapy trials at Fred Hutch and international collaborations. With over 28,000 citations on Google Scholar, he exerts substantial influence on genomic profiling, biomarker development, and therapeutic innovation in AML.